Research programme: p53 targeted cancer therapeutics - Eleos

Drug Profile

Research programme: p53 targeted cancer therapeutics - Eleos

Alternative Names: Antisense p53 therapeutics - Eleos

Latest Information Update: 18 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eleos
  • Class Antisense elements
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 18 Jul 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 12 Jul 2012 AVI Biopharma is now called Sarepta Therapeutics
  • 31 Dec 2008 The collaboration with Eleos and AVI BioPharma is still active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top